- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | PILA PHARMA AB H1 Loss Narrows | 4 | RTTNews | ||
| PILA PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.08. | Pila Pharma AB: Pila Pharma Publishes Interim Report (1 January - 30 June 2026) | 546 | GlobeNewswire (Europe) | 27 August 2026: PILA PHARMA AB (publ) (FN STO: PILA), a clinical stage biotech company pioneering development of an oral TRPV1-antagonist as a potential first-in-class treatment for obesity and diabetes... ► Artikel lesen | |
| 19.05. | Pila Pharma AB: Report From Pila Pharma Ab's Annual General Meeting 2026 | 202 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) held its Annual General Meeting today, Tuesday 19 May 2026, at the company's premises at Norra Vallgatan 72 in Malmö. Attorney Krister Hjelmstedt was elected as chairman of the... ► Artikel lesen | |
| 16.04. | Pila Pharma AB: Update To Preclinical Rat Obesity Studies - Low Exposure Of Xen-d0501 Could Explain Lack Of Effect On Bodyweight | 283 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announces that drug exposure in the obese rat studies... ► Artikel lesen | |
| 10.02. | Pila Pharma AB: Pila Pharma today publishes the Company's year-end report for the period January - December 2025. | 321 | GlobeNewswire (Europe) | The report can be found on the Company's website:
https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT
SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025)
Operating income amounted to... ► Artikel lesen | |
| 26.01. | Pila Pharma AB: Pila Pharma Signs With New Clinical Cro To Prepare For Clinical Phase In Obesity After Preclinical Obesity Studies | 466 | GlobeNewswire (Europe) | Malmö, 26 January 2026
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that... ► Artikel lesen | |
| 30.09.25 | Pila Pharma AB: Pila Pharma Enters Into Agreement With The Danish preclinical Contract Research Organisation Gubra On Preclinical Trials Of Xen-d0501 In Obesity | 741 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| ELECTRA THERAPEUTICS | 13,500 | 0,00 % | HBM Healthcare Investments AG: HBM Healthcare Investments gibt Börsengang der Portfoliogesellschaft Electra Therapeutics bekannt | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments gibt Börsengang der Portfoliogesellschaft Electra Therapeutics bekannt
21.09.2026 /... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | 0,00 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern | ||
| RECURSION PHARMACEUTICALS | 3,830 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report |
Das Unternehmen PILA PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,56 % bei einem Aktienkurs von 0,158 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.